Epitech Group and Horus Pharma Sign Global Licensing Agreement to Advance Adelmidrol Development in Eye Health

Epitech Group and Horus Pharma Sign Global Licensing Agreement to Advance Adelmidrol Development in Ophthalmology

Epitech Group S.p.A., an Italian biopharmaceutical company specializing in neuro-inflammation, and Horus Pharma, a French pharmaceutical laboratory focused on ophthalmology, have announced a global licensing agreement covering adelmidrol, a molecule belonging to the ALIAmide family developed by Epitech Group. Under the agreement, Horus Pharma will receive exclusive rights to develop and market adelmidrol for applications in human ophthalmology and periocular dermatology.

The partnership brings together Epitech Group’s more than three decades of research into ALIAmides and Horus Pharma’s established expertise in ophthalmology. Through the collaboration, the companies intend to investigate the potential of adelmidrol in addressing unmet medical needs in eye health and explore opportunities to develop new ophthalmic solutions containing the molecule.

The agreement represents a strategic collaboration between two companies with complementary scientific and commercial capabilities. Epitech Group contributes its experience in the study and development of ALIAmides, while Horus Pharma will lead the development and marketing of new products for human ophthalmology and periocular dermatology. The partnership is intended to support the exploration of adelmidrol’s potential on a global scale.

The collaboration comes amid changing healthcare needs associated with population aging, the growing prevalence of chronic diseases and the increasing complexity of ocular surface disorders. These developments are creating continued interest in new approaches to eye health, particularly solutions that may address conditions for which existing treatment options do not fully meet patient needs.

By combining their respective areas of expertise, Epitech Group and Horus Pharma aim to investigate how adelmidrol could contribute to future ophthalmic applications. The companies will bring together scientific research, product development capabilities and ophthalmology experience to explore opportunities for innovation in this therapeutic area.

Global licensing agreement grants Horus Pharma exclusive development and commercialization rights

A central element of the agreement is the grant of exclusive global rights to Horus Pharma for the development and marketing of adelmidrol in human ophthalmology and periocular dermatology. This arrangement gives Horus Pharma responsibility for advancing the molecule within the agreed application areas, including the development and commercialization of new ophthalmic solutions containing adelmidrol.

For Epitech Group, the agreement provides an opportunity to extend the potential applications of a molecule from its ALIAmide research portfolio through a partner with specialized experience in eye health. Rather than independently managing ophthalmic product development and commercialization, Epitech Group will work with Horus Pharma to explore the molecule’s opportunities in this field.

Horus Pharma’s role will be particularly important in translating the scientific interest in adelmidrol into potential products designed for ophthalmic and periocular applications. The company’s experience in ophthalmology, research and development capabilities, and international presence provide a foundation for pursuing this objective.

The agreement also reflects a shared interest in investigating new approaches to eye health. Ocular surface disorders and related conditions can present complex challenges for patients and healthcare professionals. Their management may require solutions that consider the characteristics of the affected tissues, the underlying condition and the needs of individual patients.

The partners intend to explore whether adelmidrol could offer opportunities in this area. The announcement establishes the development and commercialization framework for the collaboration, while further scientific and development work will be needed to determine the molecule’s potential in specific ophthalmic applications.

Epitech Group brings more than 30 years of ALIAmide research

Epitech Group’s contribution to the partnership is based on its long-standing research into ALIAmides and their role in physiological regulatory mechanisms. The Italian biopharmaceutical company has been studying this family of molecules for more than 30 years, building on scientific research associated with the ALIA mechanism.

The company’s research builds on the work of Rita Levi-Montalcini, the Italian neurologist and scientist who received the 1986 Nobel Prize in Physiology or Medicine. Levi-Montalcini’s scientific work included the identification of the ALIA mechanism, which provided an important foundation for subsequent research into the physiological processes associated with this area.

ALIAmides form a central part of Epitech Group’s scientific focus. Over several decades, the company has developed expertise in investigating these molecules and their potential role in physiological regulation. Adelmidrol belongs to this family and represents the molecule at the center of the new licensing agreement.

The collaboration with Horus Pharma creates an opportunity to examine adelmidrol in a specialized therapeutic field that requires particular knowledge of ocular health, ophthalmic product development and patient needs.

Epitech Group’s research experience provides the scientific foundation for the partnership, while the licensing agreement enables the molecule to be explored within Horus Pharma’s ophthalmology-focused development activities.

The agreement also reflects the importance of partnerships in translating scientific research into potential healthcare solutions. Companies with expertise in molecule research may work with specialized pharmaceutical organizations to investigate applications in therapeutic areas where dedicated development and commercialization capabilities are essential.

Through this collaboration, Epitech Group aims to support the exploration of adelmidrol beyond its existing research context and contribute to the development of potential new approaches in eye health.

Horus Pharma contributes ophthalmology expertise and international capabilities

Horus Pharma brings more than 20 years of experience in ophthalmology to the partnership. The French laboratory specializes in eye health and has established research and development capabilities, along with an international presence that can support the development and marketing of ophthalmic products.

Ophthalmology is a specialized area of medicine that covers a broad range of conditions affecting the eyes and surrounding structures. Developing solutions for this field requires an understanding of ocular physiology, disease mechanisms, formulation requirements and the practical needs of healthcare professionals and patients.

Horus Pharma’s experience in this sector is expected to support the advancement of adelmidrol for the applications covered by the agreement. The company will manage the development and marketing of new ophthalmic solutions containing the molecule, combining its expertise with Epitech Group’s research background.

The partnership also creates an opportunity for Horus Pharma to investigate a molecule developed through a research program focused on ALIAmides. By combining its ophthalmology capabilities with Epitech Group’s scientific knowledge, the company intends to explore potential new solutions for patients and healthcare professionals.

Claude Claret, CEO of Horus Pharma, highlighted the company’s interest in the molecule and the potential opportunities associated with its development.

“The work that we’ve carried out has further strengthened our interest in the potential of adelmidrol in terms of eye health and the opportunities it could unlock. We’re particularly pleased to combine our expertise with that of Epitech Group. We want to continue exploring this molecule and helping to come up with new solutions to benefit patients and healthcare professionals alike,” Claret said.

His comments underline Horus Pharma’s intention to continue investigating adelmidrol’s potential through the collaboration. The company sees the partnership as an opportunity to bring together complementary research and development capabilities while examining possible applications in ophthalmology and periocular dermatology.

Addressing evolving needs in eye health

The licensing agreement comes against a backdrop of several healthcare trends that are increasing attention on eye health. Population aging, the growing prevalence of chronic diseases and the complexity of ocular surface disorders are among the factors identified by the companies as relevant to the development of new ophthalmic solutions.

As populations age, healthcare systems face increasing demand for services and treatments addressing conditions that can affect vision, ocular comfort and overall eye health. Age-related changes and chronic health conditions can also create more complex clinical needs, requiring healthcare professionals to evaluate a broader range of factors when managing patients.

Ocular surface disorders represent an important area within ophthalmology because they can involve different structures and mechanisms affecting the surface of the eye. These conditions may require ongoing clinical assessment and management, particularly when symptoms are persistent or when multiple factors contribute to the patient’s condition.

The complexity of such disorders highlights the importance of continued research into new therapeutic approaches. Although the licensing agreement does not establish a specific clinical indication or confirm the efficacy of adelmidrol in treating an eye condition, it provides a framework for further exploration of the molecule in the agreed fields.

The companies intend to investigate opportunities for adelmidrol in human ophthalmology and periocular dermatology, with Horus Pharma leading the development and marketing of any new solutions arising from the collaboration.

This focus on unmet medical needs reflects a wider trend in pharmaceutical research, where companies are examining existing scientific discoveries and specialized molecules for potential applications in areas that may benefit from additional treatment options.

Leadership highlights the strategic importance of the collaboration

Raffaella della Valle, CEO of Epitech Group S.p.A., welcomed the agreement and emphasized Horus Pharma’s ophthalmology expertise and commitment to scientific innovation.

“We’re delighted to join forces with Horus Pharma, whose recognized ophthalmology expertise and commitment to scientific innovation make it an ideal partner. This partnership will enable us to explore prospects for this molecule in the field of eye health, on a global scale,” della Valle said.

Her comments reflect Epitech Group’s interest in working with an established ophthalmology specialist to explore adelmidrol’s potential beyond the company’s existing research activities. The global scope of the agreement also provides a framework for Horus Pharma to pursue development and marketing opportunities across international markets within the licensed application areas.

For Horus Pharma, the collaboration represents an opportunity to build on its more than two decades of ophthalmology experience while exploring a molecule developed through Epitech Group’s long-standing ALIAmide research program.

Both companies have emphasized the complementary nature of their capabilities. Epitech Group contributes scientific knowledge and experience in ALIAmide research, while Horus Pharma provides specialized ophthalmology expertise, R&D capabilities and international commercial experience.

The partnership is designed to connect these strengths in a coordinated development effort. Its objective is to investigate adelmidrol’s potential and explore whether new ophthalmic solutions containing the molecule could help address unmet needs in eye health.

Advancing research into potential ophthalmic applications

The agreement between Epitech Group and Horus Pharma highlights the role of strategic licensing partnerships in advancing pharmaceutical research. Such collaborations can enable companies to combine scientific discoveries with specialized development and commercialization capabilities, helping to explore opportunities across therapeutic areas.

In this case, the partnership connects Epitech Group’s research into ALIAmides with Horus Pharma’s focus on ophthalmology. The exclusive rights granted to Horus Pharma cover the development and marketing of adelmidrol for human ophthalmology and periocular dermatology, establishing the scope of the companies’ joint ambitions.

The collaboration is particularly relevant as healthcare providers continue to address evolving eye health needs and seek approaches that may offer additional options for patients. However, the potential clinical applications of adelmidrol will depend on further development and the evidence generated through the relevant research and evaluation processes.

For now, the announcement marks the beginning of a global collaboration focused on exploring the molecule’s opportunities in eye health. Through the agreement, Epitech Group and Horus Pharma aim to combine decades of scientific and therapeutic-area experience to support innovation in ophthalmology.

By bringing together research into ALIAmides and specialized expertise in eye care, the companies intend to investigate new possibilities for adelmidrol and work toward solutions that may benefit patients and healthcare professionals.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter